← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV21행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTPhase 2
Metoprolol (Metoprolol)
Bristol-Myers Squibb·Solid Tumor
ORR 62.11%·t½ 4 h
Overview
Program
Metoprolol
Overview
Company
Bristol-Myers Squibb
Overview
Modality
CGT
Overview
Target
Solid Tumor
Overview
Indication
Breast Cancer; Heart Failure
Overview
Phase
PHASE_2
Overview
Status
ACTIVE
MoA
Biomarker
biomarkers, suggesting that the predominant mechanism of toxic myocardial injury in this context may be elect
PK/PD
Half-life
4 h
PK/PD
Species
Rat, Human
PK/PD
Animal (cat.)
Human, Rat
PK/PD
Experiment
pharmacokinetic
Toxicology
Species
Rat, Human
Toxicology
Animal (cat.)
Human, Rat
Toxicology
Major finding
Sublethal stress from polypharmacy modulates scavenging function and fenestrations in mouse liver sinusoidal endothelial cells.. Polypharmacy, the concurrent use of multiple medications, is increasingly prevalent in older people and is associated with adverse outcomes such as falls, frailty, functional, and cognitive decline, and increased hospitalization and mortality. The liver, as the primary s…
Clinical
Primary efficacy
ORR 62.11%
Clinical
ORR
62.11%
Clinical
Result source
ClinicalTrials.gov NCT03488719
Clinical
Data Tier / Score
A · 53
Clinical
Program phase
PHASE_2
Clinical
Clinical sync
2026년 7월 12일 (1일 전)